Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics
15.5.2019 19:53:00 EEST | Business Wire | Press release
Scintomics GmbH and 1717 Life Science Ventures GmbH announced today to have signed an agreement to collaborate in the development of the theranostic pair PentixaFor / PentixaTher.
PentixaPharm GmbH, based in Würzburg, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.
Interviews: “We are delighted that in 1717 LSV we have found a strong partner with an outstanding expertise in the clinical development of precision oncologics. Taking the various recent and successful proof-of-concept studies with PentixaFor and PentixaTher in men into account, this joint venture creates optimal conditions for the effective and swift clinical development of this unrivalled and unique pair of theranostic drugs”, said Prof. Hans-Jürgen Wester, PhD, Founder of Scintomics and Chair for Pharmaceutical Radiochemistry at the Technical University of Munich (TUM), Germany.
“The introduction of 68 Ga-PentixaFor may be regarded as a milestone for clinical PET imaging of CXCR4 expressing malignancies”, added Dr. Hakim Bouterfa Co-founder of 1717 LSV GmbH and CEO of PentixaPharm. “Now we will focus on the next major step to provide CXCR4-directed endoradiotherapy in prospective clinical trials.”
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The Gallium-68 based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukaemia, lymphoma, and multiple myeloma – but also for other solid tumors like adrenocortical carcinoma, and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke and can be targeted with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalized cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics. Scintomics considers the joint venture partnership with 1717 LSV as another important milestone towards a strong positioning as radiopharmaceutical development specialist.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of targeted precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005776/en/
Contact information
For Scintomics
Saskia Kropf
General Manager
tel.
+49 8141 150 550
s.kropf@scintomics.com
www.scintomics.com
For
1717 LSV
Dr. Jens Kaufmann
General Manager
tel. +49
30 941084-422
jens.kaufmann@1717LSV.com
www.1717LSV.com
For
PentixaPharm
Dr. Hakim Bouterfa
CEO
tel. +49 172
6290822 or +49 931 304998310
hakim.bouterfa@1717LSV.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hyper-Personalization at Scale: Why Brands Must Shift to an Agentic AI Strategy3.2.2026 11:00:00 EET | Press release
Global AI-first cloud communications platform Infobip, celebrating two decades of innovation, predicts an imminent and seismic shift in brand-consumer engagement. Moving away from the current application-to-person (A2P) messaging, Infobip forecasts a widespread shift to an agent-to-person model, eventually leading to a fully autonomous agent-to-agent future by 2030. The Evolution of Engagement Swift AI adoption is driving enterprises toward agentic AI communication models, which drive autonomous customer communications across all touchpoints. This technology enables hyper-personalization across multiple channels, creating highly engaging content tailored to individual needs. Silvio Kutić, Infobip CEO, comments: “How we communicate with brands is constantly evolving. In this new agentic AI world, brands must seize the opportunity to take a holistic approach to communication. They must capitalize on the hyper-personalization made available through agentic AI and rich communication channe
Generali Deutschland AG Selects Clearwater Analytics to Modernize and Scale Investment Operations Unit-Linked Fund Business3.2.2026 10:00:00 EET | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, announced today that Generali Deutschland AG has selected CWAN’s investment management platform for its €40 billion unit-linked fund (ULF) life insurance business, unifying processes across four subsidiaries and preparing the group for accelerated growth in one of Europe’s fastest-expanding sectors. The partnership reflects a strategic move ahead of unprecedented market expansion. The global unit-linked insurance market reached $906.9 billion in 2023 and is projected to grow at 10.9% annually through 2032, reaching $2.3 trillion, according to Allied Market Research. This growth trajectory is creating competitive separation between insurers capable of scaling operations and those constrained by fragmented systems across multiple European jurisdictions. Under a multi-year agreement, Generali Deutschland will consolidate portfolio management, order execution, and reconciliation on CWAN
Corona Cero Unveils Global Roster of Athlete Ambassadors to Champion TIME CERO at Milano Cortina 20263.2.2026 10:00:00 EET | Press release
Corona Cero today unveiled its global roster of brand ambassadors who will champion TIME CERO, the brand’s new initiative created in partnership with the IOC and Athlete365, throughout the Olympic Winter Games. Together, Team Corona Cero will bring the brand’s “For Every Golden Moment” global platform to life, reminding people that meaningful golden moments can happen anytime, anywhere, or in any season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203205858/en/ Team Corona Cero Central to Corona Cero’s commitment as a Worldwide Olympic Partner, TIME CERO is designed to celebrate Olympians and help them relax, stay present, and embrace balance amid the intensity of competition. Activated across a range of Olympic Games locations, all Winter Olympians at Milano Cortina 2026 will be able to embrace TIME CERO through nature-inspired spaces and post-competition retreats. “'For Every Golden Moment’ is more than medals or mil
Ares Completes Acquisition of BlueCove to Launch Systematic Credit Strategy3.2.2026 10:00:00 EET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that it has completed its acquisition of all outstanding shares of BlueCove Limited (“BlueCove”), a London-based systematic fixed-income manager. The integrated BlueCove business will operate as Ares Systematic Credit, the latest strategy within the Ares Credit Group. Ares Systematic Credit offers systematic fixed-income strategies that harness the power of data and technology to deliver differentiated solutions to investors. The strategy leverages proprietary technology to support an evidence-based and data-driven investment process across high-yield, investment grade corporates, convertible bonds, and other liquid credit instruments in a variety of portfolio constructions. These methods seek to systematically access, select, analyze and deploy information to capitalize on market inefficiencies and generate high-quality alpha. Led by Alex Khein, most recently CEO of Blue
Owl Labs Unveils Next-Generation Meeting Owl 5 Pro, Expanding Enterprise Hybrid Collaboration3.2.2026 10:00:00 EET | Press release
Owl Labs, a leader in 360-degree AI-powered video conferencing and hybrid collaboration technology, today announcedthe Meeting Owl 5 Pro, itsnewest 360-degree camera, speaker, and mic device. The Meeting Owl 5 Pro reimagines the centre-of-table experience for hybrid meetings with a solution purpose-built for enterprise organisations, delivering a seamless single-cable Bring Your Own Device (BYOD) experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203914393/en/ The Meeting Owl 5 Pro is Owl Labs' newest 360-degree camera, speaker, and mic device. Flexibility is foundational to the Meeting Owl 5 Pro’s design, enabling it to support virtually any room setup—from standalone BYOD setups to integration as a peripheral within full in-room systems. A single-cable BYOD experience enables instant USB connectivity to the room’s A/V system, simplifying room setup, reducing cabling complexity, and ensuring a consistent experien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom